These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14769687)

  • 1. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods.
    Pieper KS; Tsiatis AA; Davidian M; Hasselblad V; Kleiman NS; Boersma E; Chang WC; Griffin J; Armstrong PW; Califf RM; Harrington RA
    Circulation; 2004 Feb; 109(5):641-6. PubMed ID: 14769687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
    Elmouchi DA; Bates ER
    Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
    Tricoci P; Peterson ED
    J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Percutaneous coronary interventions in elderly patients: clinical indications and adjunctive medical treatment. The Italian Drug Evaluation in Angioplasty (IDEA) study].
    Bossi I; Piccaluga E; Scatturin M; Corvaja N; Pasquetto G; Steffanon L; Oberhollenzer R; Colombo P; Bolognese L; Savonitto S
    G Ital Cardiol (Rome); 2006 Feb; 7(2):136-44. PubMed ID: 16532725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies on glycoprotein IIb/IIIa receptor antagonist].
    Rasmussen LH; Husted SE; Clemmensen PM; Gøtzsche CO; Helqvist S; Kristensen SD; Pedersen KE; Rasmussen K; Rasmussen S
    Ugeskr Laeger; 2000 Oct; 162(44):5944-7. PubMed ID: 11094564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
    Shimpi RA
    J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute coronary syndromes without ST-segment elevation. From randomized clinical trials, to consensus guidelines, to clinical practice in Italy: need to close the circle].
    Savonitto S; Klugmann S
    Ital Heart J Suppl; 2004 Mar; 5(3):167-76. PubMed ID: 15116860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
    Sabatine MS; Hamdalla HN; Mehta SR; Fox KA; Topol EJ; Steinhubl SR; Cannon CP
    Am Heart J; 2008 May; 155(5):910-7. PubMed ID: 18440341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPIIb-IIIa receptor inhibitors: what the interventional radiologist needs to know.
    Hofmann LV; Razavi M; Arepally A; Reginelli JP; Resar J; Geschwind JF; Corl F
    Cardiovasc Intervent Radiol; 2001; 24(6):361-7. PubMed ID: 11907740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
    Jonas M; Stone GW; Mehran R; Hermiller J; Feldman R; Herrmann HC; Cox DA; Kuntz RE; Popma JJ; Rogers C;
    Eur Heart J; 2006 Apr; 27(8):920-8. PubMed ID: 16415300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction--the RADIAL-AMI pilot randomized trial.
    Cantor WJ; Puley G; Natarajan MK; Dzavik V; Madan M; Fry A; Kim HH; Velianou JL; Pirani N; Strauss BH; Chisholm RJ
    Am Heart J; 2005 Sep; 150(3):543-9. PubMed ID: 16169338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.